Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Adjuvant sorafenib na RFA verbetert prognose van HCC-patiënten
aug 2022 | Maag-darm-leveroncologie